secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tarsus Pharmaceuticals, Inc. (TARS)
CIK:        0001819790
Form:       8-K
Filed at:   2023-12-11T23:59:59+00:00
Accession:  0001819790-23-000088
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tarsus announces positive topline Phase 2a results for TP-03 in MGD with Demodex mites
--------------------------------------------------------------------------------

- Ersa trial evaluated TP-03 (lotilaner ophthalmic solution, 0.25%) BID or TID for 12 weeks.
- Trial enrolled Meibomian Gland Disease patients with Demodex mites.
- Company states positive topline results; detailed data presented in corporate deck.
- No specific efficacy or safety numbers disclosed in the 8-K filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819790/000181979023000088/0001819790-23-000088-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819790/000181979023000088/tars-20231211.htm
  HTML page:      https://secwatch.observer/filing/0001819790-23-000088

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer